In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. July 23, 2018. Anne Gaynor.

Executive Summary

The US FDA Blood Products Advisory Committee has recommended the down-classification of many HIV tests. See what Anne Gaynor, manager of HIV, Hepatitis, STD and TB programs at the Association of Public Health Laboratories (and a member of the committee) said about it here.

"The decision to regulate these devices under class III controls was made decades ago when little hope could be offered to those who became infected with these debilitating viruses, and in the case of HIV, diagnosis equated to a death sentence. Since that time we have made significant gains in our knowledge about these viruses and our ability to treat the infections they cause through research and epidemiological studies." –Anne Gaynor, manager of HIV, Hepatitis, STD and TB programs, Association of Public Health Laboratories

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts